Brett Haumann is a seasoned pharmaceutical physician and senior executive with more than 25 years of experience in the pharmaceutical and biotechnology sector, having served as a non-executive director on a number of private and public boards in Europe and the US. He was formerly Head of the R&D Committee on the Board of Aimmune Therapeutics (2018-2020), which launched Palforzia® for the treatment of peanut allergy prior to its acquisition by Nestlé in 2020.
​
Dr. Haumann is a physician with an MBBCh degree from the University of Witwatersrand in South Africa and an MBA degree with distinction from Open University in the UK.